Blog

Cathy Eng: Congrats to Pfizer and all the colorectal cancer patients with treatment-naive metastatic CRC

Cathy Eng/X

Dec 30, 2024, 13:08

Cathy Eng: Congrats to Pfizer and all the colorectal cancer patients with treatment-naive metastatic CRC

Cathy Eng, Associate Director of Vanderbilt-Ingram Cancer Center, shared a post on LinkedIn:

“Congrats to Pfizer and all the colorectal cancer patients with treatment-naive BRAFV600E MT metastatic CRC.

BREAKWATER is a phase III trial of FOLFOX +/- encorafenib and cetuximab in treatment naive patients.

BRAFV600E MT = 9% of all mCRC pts
Poor prognostic indicator if MSI-S
Confirmed objective response rate (ORR) assessed by blinded independent central review and evaluated in the first 110 patients randomized in each arm.
ORR was 61% (95% CI: 52%, 70%) in the encorafenib+ cetuximab, + mFOLFOX6 arm and 40% (95% CI: 31%, 49%) in the control arm.
Median DoR was 13.9 months (95% CI: 8.5, not estimable) and 11.1 months (95% CI: 6.7, 12.7) in the control arm.
PFS and OS: TBD
More to follow.”

Read further.

More posts featuring Cathy Eng.

Cathy Eng is a Professor of Medicine, Hematology and Oncology, and is the Co-Director of GI Oncology, Associate Director of Strategic Relations and Research Partners and Co-Leader of the Gastrointestinal Cancer Research Program at the Vanderbilt-Ingram Cancer Center.

She also holds the David H. Johnson Endowed Chair of Surgical and Medical Oncology. Dr. Eng was previously a Professor of Medical Oncology at The University of Texas MD Anderson Cancer Center. Her primary clinical research interests include clinical trials involving innovative drugs for the treatment of colorectal, anal, and appendiceal cancers.

She has a specific interest in young colorectal cancer patients as well as the role of immunotherapy in HPV-associated cancers. Nationally, Dr. Eng has served in multiple leadership roles for ASCO, ASCO GI, ECOG, and the NCI Rectal/Anal Task Force.

She has most recently been chosen to serve as the Vice-Chair for the SWOG GI Committee and the NCI GI Steering Committee.